Table 1 Electrophysiological measures, cumulative dose, duration of treatment and follow-up
PatientsSural SAPa (uV)Cumulative dose total* (G)Therapy* (months)Sural SAPa* (%)Therapy** (months)Sural SAPa** (%)Total duration therapy (months)FU (months)Sural SAPa FU (%)
1112311−7010.5−80.921.527−26
213.712.510−720−721036.50
33.94029−1008.5−10037.530−100
49.521.417−1000−1001744−73.6
5320.515−1004.5−10019.547−100
622.612.714−5217.5−73.831.533.5−69
715.424.819−535−482424−46
8199.44.5−525−759.533−76
913.12212−5414−612625.5−75.5
10736.912.5−440−4412.535−40
114.59.522−400−402240.5−40
121210.67000</emph>7100

  • Sural SAPa: sural sensory action potential amplitude (uV) at enrolment time.

  • Cumulative dose total*: total thalidomide cumulative dose (g) at time of reduction in sural nerve SAP amplitude.

  • Therapy*: duration of treatment at time of reduction in sural nerve SAP amplitude.

  • Sural SAPa*: percentage of sural SAP amplitude reduction referred to baseline value.

  • Therapy**: duration of treatment after detection of reduction in SAP amplitude (months).

  • Sural SAPa**: percentage of sural SAP amplitude reduction at stop therapy referred to baseline value.

  • Total duration therapy: months of therapy.

  • FU: follow-up after thalidomide discontinuation (months).

  • Sural SAPa FU: percentage of sural SAP amplitude reduction at follow-up referred to baseline value.